Confidentiality For Proprietary Information Drives FDA Plan To Generate More CBD Safety Data
Executive Summary
In report to Congress about determining an enforcement discretion policy for CBD-containing non-drug products, FDA described challenges it faces, largely unique in its history, in determining whether hemp-derived ingredients are safe in food, supplements and other products that already are “sold increasingly widely."
You may also be interested in...
US Cardiac Arrhythmia Case Could Stoke International CBD Safety Worries
A patient admitted to a US emergency department after experiencing dizziness and fainting without warning is found to have been using a cocktail of herbal dietary supplements, including CBD and CBG. The case could fuel international worries about CBD's safety, for example in the EU, where novel food applications were recently put on hold by EFSA because of safety data gaps.
EU CBD Novel Food Applications On Hold As EFSA Considers Health Risks
All European Union CBD novel food applications have been paused by EFSA after its Panel on Nutrition, Novel Foods and Food Allergens raised concerns about the ingredient's safety, pointing in a wide-ranging scientific literature review to a number of data gaps related to bioavailability, liver damage, gastrointestinal issues and possible negative impacts on pregnancy and reproductive health.
Hemp Roundtable Says Safety Study Data Should Convince Congress On Lawful CBD Use
Study of 1,061 subjects showed oral CBD has robust safety profile, addressing FDA’s safety concerns and providing evidence to convince agency to take action on CBD regulation, say trade groups.